REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 15th, 2024 • MediWound Ltd. • Medicinal chemicals & botanical products
This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 15, 2024, between MediWound Ltd., an Israeli company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • February 25th, 2020 • MediWound Ltd. • Medicinal chemicals & botanical products • New York
MediWound Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), the Company’s ordinary shares, NIS 0.01 par value per share (the “Ordinary Shares”), on the terms set forth in this agreement (this “Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 26th, 2022 • MediWound Ltd. • Medicinal chemicals & botanical products • New York
This securities purchase agreement (this “Agreement”) is dated as of September 22, 2022, between MediWound Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages attached hereto (each, including its successors and assignees, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 7th, 2023 • MediWound Ltd. • Medicinal chemicals & botanical products • New York
This securities purchase agreement (this “Agreement”) is dated as of February 3, 2023, between MediWound Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages attached hereto (each, including its successors and assignees, a “Purchaser” and collectively the “Purchasers”).
4,400,000 Ordinary Shares Par Value NIS 0.01 MEDIWOUND LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • September 19th, 2017 • MediWound Ltd. • Medicinal chemicals & botanical products • New York
5,208,333 Ordinary Shares MEDIWOUND LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • March 3rd, 2022 • MediWound Ltd. • Medicinal chemicals & botanical products
MediWound Ltd., an Israeli company (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 5,208,333 ordinary shares (the “Firm Shares”) of the Company, par value NIS 0.01 per share (the “Ordinary Shares”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 781,249 Ordinary Shares (the “Option Shares”) from the Company for the purpose of covering over‑allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
SHARE PURCHASE AGREEMENTShare Purchase Agreement • July 15th, 2024 • MediWound Ltd. • Medicinal chemicals & botanical products • New York
This Share Purchase Agreement (this “Agreement”) is dated as of July 15, 2024, between MediWound Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”).
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of , 20 , is entered into by and between MediWound Ltd., an Israeli company whose address is 42 Hayarkon Street, Yavne 81227 , Israel (the “Company”), and , the/a [insert position of the officer] of the Company whose address is (the “Indemnitee”).
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT MEDIWOUND LTD.Placement Agent Ordinary Share Agreement • September 26th, 2022 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) four (4) year anniversary of the Initial Exercise Date and (ii) September 22, 2027 (the “Termination Date”), but not thereafter, to subscribe for and purchase from MEDIWOUND LTD., an Israeli company (the “Company”), up to ______ Ordinary Shares, NIS 0.01 par value (the “Ordinary Share(s)”) (as subject to adjustment hereunder, the “Warrant Shares”) of the Company. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain engagement letter, dated as of August
MEDIWOUND LTD.2014 Equity Incentive Plan • February 25th, 2020 • MediWound Ltd. • Medicinal chemicals & botanical products
PATENT PURCHASE AGREEMENT (the “Agreement”) Between MEDIWOUND LTD. a limited liability company incorporated under the laws of Israel, of 42 Hayarkon Street, Yavne 81227, Israel (“MediWound”) and Omer 84965, Israel (“LR”) (together, the “Parties”)Patent Purchase Agreement • February 10th, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
WHEREAS, LR represented to MediWound that it owns all rights in and to certain Patents (defined below) which Patent refers to LR’s multipurpose dynamic occlusive dressing including without limitation an adhesive barrier; and
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT MEDIWOUND LTD.Pre-Funded Ordinary Share Agreement • September 26th, 2022 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from MEDIWOUND LTD., an Israeli company (the “Company”), up to ______ Ordinary Shares, NIS 0.01 par value (the “Ordinary Share(s)”) (as subject to adjustment hereunder, the “Warrant Shares”) of the Company. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Unprotected Sub-Lease AgreementSub-Lease Agreement • February 10th, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
Clal Life Sciences L.P. Partnership No. 550208375 Whose address for the purposes hereof is: 42 Hayarkon Street Yavne 81227 (hereinafter the “CLS”)
MediWound Ltd. June 19, 2007License Agreement • February 10th, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
*** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission.
SERIES A ORDINARY SHARE PURCHASE WARRANT MEDIWOUND LTD.Series a Ordinary Share Purchase Agreement • September 26th, 2022 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS SERIES A ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the four (4) year anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from MEDIWOUND LTD., an Israeli company (the “Company”), up to ______ Ordinary Shares, NIS 0.01 par value (the “Ordinary Share(s)”) (as subject to adjustment hereunder, the “Warrant Shares”) of the Company. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
MediWound Ltd. and Challenge Bioproducts Corporation Ltd.Supply Agreement • February 10th, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
This Supply Agreement (“Agreement”) was made and entered into as of the 11 day of January, 2001 by and between MediWound Ltd., a corporation organized and existing under the laws of Israel (hereinafter referred to as “MediWound”) and Challenge Bioproducts Corporation Ltd., a corporation organized and existing under the laws of the Republic of China (hereinafter referred to as “CBC”) and amended by the parties on February 28, 2010 (“Amendment Effective Date”).
FOUNDERS AND SHAREHOLDERS AGREEMENTFounders and Shareholders Agreement • February 10th, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
Unprotected Lease Agreement Entered into and executed in Tel Aviv as of this 13th day of July 2023Lease Agreement • March 21st, 2024 • MediWound Ltd. • Medicinal chemicals & botanical products
Between: YEZUM-TECH BUSINESS AND ASSETS LTD (Company Reg. No. 51-152477-9) Of 24 Shai Agnon St. (apt. 28), Tel Aviv (Hereinafter: the “Lessor”) The first party;
LICENSE AGREEMENTLicense Agreement • February 21st, 2017 • MediWound Ltd. • Medicinal chemicals & botanical products
WHEREAS, LR represents that it owns all rights in and to the patent application known as PCT/IL2009/000946 and (the "Patent"), which Patent relates to a wound dressing and methods of preparation and use thereof for promoting healing of wound bed. In particular, the wound dressing is advantageous for application to a debrided wound bed. The wound dressing comprises an open conduit polymeric foam matrix, and a hydrophilic polymer which is disposed in dry form on the inner surfaces of the conduits within the matrix (“the Dressing”); and
TURNKEY PROJECT AGREEMENT This Agreement is made the 17 day of July 2023Turnkey Project Agreement • March 21st, 2024 • MediWound Ltd. • Medicinal chemicals & botanical products
Mediwound Ltd. registration number 512894940, a company incorporated in Israel and having its principal place of business at 42 Ha’Yarkon St., Yavne 8122745 Israel (the “Customer”)
Unprotected Sublease AgreementSublease Agreement • March 19th, 2018 • MediWound Ltd. • Medicinal chemicals & botanical products
Addendum to Unprotected Sublease Contract dated March 18th, 2018 made and signed in Tel Aviv on February 3rd, 2019Unprotected Sublease Contract • March 25th, 2019 • MediWound Ltd. • Medicinal chemicals & botanical products
Whereas on 18.03.2018, an unprotected sublease contract was signed between the Lessor and the Lessee (the "Lease Agreement") in relation to the leasehold as defined in the Lease Agreement, which is located at parcel 3 on block 4939 in Yavne Industrial Zone including the structure built on it (the "Original Leasehold");
MediWound Ltd. Yavne IsraelInformation Rights Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
This letter confirms our agreement and undertaking that subject to and following the initial public offering of the ordinary shares of MediWound Ltd. (the “Company”) on the Nasdaq Global Market, provided that such offering is consummated not later than August 31, 2014, Clal Biotechnology Industries Ltd. (the “Shareholder”) shall be entitled to the information rights set forth in this letter agreement (this “Agreement”), subject to the terms set forth herein.
AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) RATING PAGE OF PAGESContract • March 25th, 2019 • MediWound Ltd. • Medicinal chemicals & botanical products
* * * ] Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.Contract • February 25th, 2021 • MediWound Ltd. • Medicinal chemicals & botanical products
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of this day of March 2014, by and among (i) MediWound Ltd., an Israeli company (the “Company”), and (ii) each holder of the Company’s Ordinary Shares, nominal value NIS 0.01 each (“Ordinary Shares”) listed on Schedule A hereto (the “Shareholders”).
* * * ] Portions of this agreement were omitted and a complete copy of this agreement has been provided separately to the Securities and Exchange Commission pursuant to the company’s application requesting confidential treatment under Rule 24b-2 of...Contract • January 25th, 2016 • MediWound Ltd. • Medicinal chemicals & botanical products
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASESettlement Agreement • March 25th, 2019 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE (the "Settlement Agreement") is made and entered into this 24th day of March, 2019 (the "Effective Date"), by and between Teva Pharmaceutical Industries Ltd. ("Teva"), on the one hand, and MediWound Ltd. ("MediWound"), on the other hand. Teva and MediWound are together referred to as the "Parties" and individually referred to as a “Party”.
February 18, 2014 Letter Agreement Re: Post-Repurchase TermsLetter Agreement Re: Post-Repurchase Terms • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
This shall serve to confirm the agreements between Teva Pharmaceutical Industries Ltd. (“Teva”) and MediWound Ltd. (“MediWound”) with respect to the matters set forth below:
Amendment No. 1 to Settlement Agreement and Mutual General ReleaseSettlement Agreement and Mutual General Release • February 25th, 2021 • MediWound Ltd. • Medicinal chemicals & botanical products
This Amendment No.1 to a Settlement Agreement and Mutual General Release (“Amendment”) is made effective of December 13, 2020 (the “Effective Date”) by end between Teva Pharmaceutical Industries Ltd. ("Teva"), on the one hand, and MediWound Ltd. ("MediWound"), on the other hand. Teva and MediWound are together referred to as the "Parties" and individually referred to as a “Party”.
Amendment No.2 to Settlement Agreement and Mutual General ReleaseSettlement Agreement and Mutual General Release • July 15th, 2024 • MediWound Ltd. • Medicinal chemicals & botanical products
This Amendment No.2 to Settlement Agreement and Mutual General Release (this “Second Amendment”) is made effective of July 15, 2024 (the “Effective Date”) by and between Teva Pharmaceutical Industries Ltd. ("Teva"), on the one hand, and MediWound Ltd. ("MediWound"), on the other hand. Teva and MediWound are together referred to as the "Parties" and individually referred to as a “Party”.
COLLABORATION AND RIGHTS AGREEMENTCollaboration and Rights Agreement • July 15th, 2024 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS COLLABORATION AND RIGHTS AGREEMENT (this “Agreement”), is made as of July 15, 2024, by and between MediWound Ltd., an Israeli company (“MediWound”), and Molnlycke Health Care AB, a Swedish corporation (“Mölnlycke”). Each of MediWound and Mölnlycke shall be referred to herein as a “Party” and collectively as the “Parties”.
